| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910820655103321 |
|
|
Autore |
MacArthur Julie <1982-> |
|
|
Titolo |
Cartography and the political imagination : mapping community in colonial Kenya / / Julie MacArthur |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Athens, Ohio : , : Ohio University Press, , 2016 |
|
©2016 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (357 pages) : illustrations, maps, photographs, tables |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Luyia (African people) - Kenya - History |
Ethnicity - Political aspects - Kenya |
Cartography - Political aspects - Kenya |
Cartography - Social aspects - Kenya |
Kenya Ethnic relations History |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Bibliographic Level Mode of Issuance: Monograph |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Mapping political communities in Africa -- The geographies of western Kenya -- Land, gold, and commissioning the "tribe" -- Ethnic patriotism in the interwar years -- Speaking Luyia: linguistic work and political imagination -- Mapping gender: moral crisis and the limits of cosmopolitan pluralism in the 1940s -- Between loyalism and dissent: ethnic geographies in the era of Mau Mau -- Mapping decolonization -- Beyond the ethnos and the nation. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Mapping political communities in Africa -- The geographies of western Kenya -- Land, gold, and commissioning the "tribe"--Ethnic patriotism in the interwar years -- Speaking Luyia: linguistic work and political imagination -- Mapping gender: moral crisis and the limits of cosmopolitan pluralism in the 1940s -- Between loyalism and dissent: ethnic geographies in the era of Mau Mau -- Mapping decolonization -- Beyond the ethnos and the nation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9911009206603321 |
|
|
Autore |
Isa Rehanet |
|
|
Titolo |
Intellectual Capital Disclosure and Performance of Consumer Goods Firms |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Newcastle-upon-Tyne : , : Cambridge Scholars Publishing, , 2024 |
|
©2024 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (218 pages) |
|
|
|
|
|
|
Altri autori (Persone) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Intellectual capital - Management |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Sommario/riassunto |
|
Business executives and managers are increasingly working in a highly competitive environment, where identifying the main drivers of performance is vital for the survival of firms. Intellectual capital is a crucial matter for firms worldwide, and the disclosure of intellectual capital has been identified as one of the major drivers of performance. This book examines the impact of intellectual capital disclosure on the performance of listed firms which adopt the balanced scorecard approach. The book is a product of research that offers innovative analysis and proves that managers of firms can use the disclosure of intellectual capital to boost performance. It reveals how using the balanced scorecard as a measurement tool for intellectual capital disclosure can drive the performance of firms. Students in postgraduate programmes and academics, as well as business executives and managers, will find this book to be an essential guide to maximizing intellectual capital disclosure to boost performance. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3. |
Record Nr. |
UNINA9911019528803321 |
|
|
Autore |
Hauschke Dieter |
|
|
Titolo |
Bioequivalence studies in drug development : methods and applications / / Dieter Hauschke, Volker Steinijans, Iris Pigeot |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Chichester, West Sussex, England ; ; Hoboken, NJ, : Wiley, c2007 |
|
|
|
|
|
|
|
ISBN |
|
9786610838806 |
9781280838804 |
1280838809 |
9780470094778 |
047009477X |
9780470094761 |
0470094761 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (330 p.) |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Altri autori (Persone) |
|
SteinijansVolker |
PigeotIris |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Drugs - Therapeutic equivalency |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and indexes. |
|
|
|
|
|
|
Nota di contenuto |
|
Bioequivalence Studies in Drug Development; Contents; Preface; 1 Introduction; 1.1 Definitions; 1.1.1 Bioavailability; 1.1.2 Bioequivalence; 1.1.3 Therapeutic equivalence; 1.2 When are bioequivalence studies performed; 1.2.1 Applications for products containing new active substances; 1.2.2 Applications for products containing approved active substances; 1.2.3 Applications for modified release forms essentially similar to a marketed modified release form; 1.3 Design and conduct of bioequivalence studies; 1.3.1 Crossover design and alternatives; 1.3.2 Single- vs. multiple-dose studies |
1.3.3 Pharmacokinetic characteristics1.3.4 Subjects; 1.3.5 Statistical models; 1.3.5.1 Average bioequivalence; 1.3.5.2 Population bioequivalence; 1.3.5.3 Individual bioequivalence; 1.3.6 Sample size; 1.4 Aims and structure of the book; References; 2 Metrics to characterize concentration-time profiles in single- and multiple-dose bioequivalence studies; 2.1 Introduction; 2.2 Pharmacokinetic characteristics (metrics) for single-dose studies; 2.2.1 Extent of |
|
|
|
|
|
|
|
|
|
|
|
bioavailability; 2.2.2 Rate of bioavailability; 2.3 Pharmacokinetic rate and extent characteristics (metrics) for multiple-dose studies |
2.4 ConclusionsReferences; 3 Basic statistical considerations; 3.1 Introduction; 3.2 Additive and multiplicative model; 3.2.1 The normal distribution; 3.2.2 The lognormal distribution; 3.3 Hypotheses testing; 3.3.1 Consumer and producer risk; 3.3.2 Types of hypotheses; 3.3.2.1 Test for difference; 3.3.2.2 Test for superiority; 3.3.2.3 Test for noninferiority; 3.3.2.4 Test for equivalence; 3.3.3 Difference versus ratio of expected means; 3.3.3.1 The normal distribution; 3.3.3.2 The lognormal distribution; 3.4 The RT/TR crossover design assuming an additive model |
3.4.1 Additive model and effects3.4.2 Parametric analysis based on t-tests; 3.4.2.1 Test for difference in carryover effects; 3.4.2.2 Test for difference in formulation effects; 3.4.2.3 Test for difference in period effects; 3.4.3 Nonparametric analysis based on Wilcoxon rank sum tests; 3.4.3.1 Test for difference in carryover effects; 3.4.3.2 Test for difference in formulation effects; 3.4.3.3 Test for difference in period effects; References; 4 Assessment of average bioequivalence in the RT/TR design; 4.1 Introduction; 4.2 The RT/TR crossover design assuming a multiplicative model |
5 Power and sample size determination for testing average bioequivalence in the RT/TR design |
|
|
|
|
|
|
Sommario/riassunto |
|
Studies in bioequivalence are the commonly accepted method to demonstrate therapeutic equivalence between two medicinal products. Savings in time and cost are substantial when using bioequivalence as an established surrogate marker of therapeutic equivalence. For this reason the design, performance and evaluation of bioequivalence studies have received major attention from academia, the pharmaceutical industry and health authorities. Bioequivalence Studies in Drug Development focuses on the planning, conducting, analysing and reporting of bioequivalence studies, covering all aspects r |
|
|
|
|
|
|
|
| |